Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ophthalmic Devices Panel Supports Safety For Ocular Therapeutix’ ReSure Sealant, But Other Votes Mixed

This article was originally published in The Gray Sheet

Executive Summary

The FDA panel voted 9-1 in favor of the safety of Ocular’s PMA Sept. 19, but 5-1 on whether the benefits of the device, an in situ-formed hydrogel that creates an adherent temporary, soft and lubricious sealant to prevent leakage from clear corneal incisions, outweigh its risk, and 5-3 on its effectiveness. Multiple panelists abstained from the last two votes based on concerns with wording of the indication.

You may also be interested in...

New Product Briefs: ReSure Sealant, Direct Flow TAVR; DePuy Spine Device

Ocular Therapeutix’s ReSure Sealant gains PMA approval for sealing cataract surgery incisions. Direct Flow gains CE mark for larger version of its repositionable transcatheter aortic valve replacement. More product news.

News In Brief

Industry urges restraint at 510(k) modifications meeting. User fee sequestration unaddressed at House Appropriations Committee markup. More news

Second Judge Rejects Constitutional Challenges To Medicare Price Negotiation Program

Delaware district judge rules against AstraZeneca’s claim the IRA violates its due process rights, echoing findings made by Ohio district judge in Chamber of Commerce’s suit. Only other IRA ruling to date dismissed PhRMA’s complaint on procedural grounds without addressing the merits.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts